to assess the safety and efficacy of delayed-release mesalazine ( 5-aminosalicylic acid ) as maintenance treatment for patients with ulcerative colitis , 100 patients with quiescent colitis were randomly grouped to receive either delayed-release mesalazine or an equivalent dose of enteric-coated sulfasalazine in a 48-wk trial .
C0009324
ulcerative
C0009319
colitis